|
|
Article: Hard to Treat Diseases Inc. (HTDS) Targets an EU Based Stem Cell Research Company for a Merger.
- Article from:
- PR Newswire
- Article date:
- October 29, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FRANKFURT, Oct. 29 /PRNewswire-FirstCall/ -- Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica Bio Chem, announces that it is targeting an EU based company, and has initiated talks that may involve a merger.
Hard to Treat Diseases Inc. (HTDS) and the newly targeted company, which does not wish to disclose its name at the present stage of negotiations, started talks about the possibilities for future cooperation and are in the process of reviewing initial documentation. The new company would give HTDS a new competitive edge on the pharmaceutical market, including providing HTDS with an increased revenue base.
...